Nahum Puebla-Osorio, D.V.M., Ph.D.
Department of Thoracic Radiation Oncology, Division of Radiation Oncology
Present Title & Affiliation
Primary Appointment
Assistant Professor, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston
Dual/Joint/Adjunct Appointment
Assistant Professor, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston
Research Interests
My research interest centers on investigating the impact of low-dose radiotherapy on the metabolic status of adoptively transferred T cells, including Tumor-Infiltrating Lymphocytes (TILs) or Chimeric Antigen Receptor T cells (CAR T). I am particularly focused on exploring the synergies between low-dose radiotherapy and cell therapy to enhance clinical outcomes. This research aims to shed light on the intricate interplay between radiation, cellular metabolism, and immune responses, ultimately contributing to developing more effective and targeted cancer therapies
Education & Training
Degree-Granting Education
| 2023 | The University of Texas McCombs School of Business, Houston, US, Data Science, Data Science and Business Analytics |
| 2004 | Texas A&M University, College Station, US, Comparative Immunology, Ph.D |
| 2000 | Texas A&M University, College Station, US, Comparative Physiology, M.S |
| 1990 | National Autonomous University of Mexico (UNAM), Mexico City, MX, Animal Pathology, DVM |
Postgraduate Training
| 2024-2024 | Advanced Python for Machine Learning and Artificial Intelligence, Machine Learning/Artificial Intelligence, Great Learning Education Services, Austin, Texas |
| 2023-2023 | Postgraduate Fellow, Data Science and Business Analytics (Machine Learning and AI), The University of Texas, Austin, Texas |
| 2004-2009 | Posdoctoral Fellow, DNA repair, Genomic instability, Molecular immunology, M.D. Anderson Cancer Center, Houston |
Experience & Service
Faculty Academic Appointments
Instructor, Lymphoma/Myeloma - Research, The University of Texas MD Anderson Cancer Center, Houston, 2015 - 2016
Instructor, Immunology, The University of Texas MD Anderson Cancer Center, Houston, 2009 - 2015
Other Professional Positions
Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - 2009
Research Associate, Texas A & M University, College Station, TX, 1998 - 2000
Research Assistant, Texas A & M University, College Station, TX, 1997 - 1998
Technical Manager, Technical Service Department, Applied Research, Tehuacan, 1993 - 1997
Product Manager, Technical Service Department, Sanofi Animal Health, Mexico City, 1992 - 1993
Technical Advisor, Technical Service Department, Animal Nutrition Co, Mexico City, 1991 - 1992
Teaching Assistant, College of Veterinary Medicine, UNAM, Mexico City, 1990 - 1991
Editorial Activities
Lead editor, Frontiers in Immunology, 2024 - Present
Honors & Awards
| 2013 - 2015 | Minority supplement to promote diversity in health-related research, National Institute for Allergy and Infectious Diseases (NIAID) |
| 2010 - 2011 | Minority supplement to promote diversity in health-related research, National Cancer Institute (NCI) |
| 2009 | Minority Scholarship from the Keystone Symposium meeting on the Biology of Aging, The Keystone Symposium |
| 2007 | Scholarship from the Keystone Symposium meeting on Genomic Instability and Repair, The Keystone Symposium |
| 2003 | The Bessoudo Scholarship, Texas A&M College of Agriculture and Life Sciences |
| 2002 | Scholarship from the Gordon Research Conference on Mechanisms of Toxicity, The Gordon Research Conference |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2018. The tumor microenvironment in follicular lymphoma. Conference. Grand Rounds Committee. Houston.
National Presentations
- 2007. Role of ATM in V(D)J recombination and cell cycle control. Invited. 94th Annual Meeting of the American Association of Immunologists. Miami Beach, FL, US.
- 2007. Early embryonic lethality due to targeted inactivation of DNA Ligase III. Invited. Genome Instability and Repair. Breckenridge, CO, US.
- 2007. DNA damage-induced cellular senescence is sufficient to supproess tumorigenesis. Invited. Genome Instability and Repair. Breckenridge, CO, US.
- 2004. Downregulation of MMP-2 and MMP-9 in the LPS-stimulated HD11 chicken macrophage cell line by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Invited. Mechanisms of Toxicity. Waterville, ME, US.
- 2002. Transcriptome analysis of the chicken DT40 B lymphocyte cell line: modulation by TCDD. Invited. Mechanisms of Toxicity. Lewiston, ME, US.
International Presentations
- 2026. Geometric Adversarial Learning for Reconstruction of Right-Censored Tumor Dynamics. Invited. Society for Mathematical Biology. Graz, AT.
- 2014. The role of NHEJ in the repair of damaged DNA during HPV infection. Invited. International Meeting on Women’s Cancer. Toluca, MX.
- 2012. NHEJ Deficiency and impaired p53-dependent apoptosis lead to colorectal dysfunction in mice. Invited. Colorectal Cancer Workshop. Oslo, NO.
- 2011. Physiology of the gonadotropins in the avian embryo. Invited. 8th International Symposium on Avian Endocrinology. Scottsdale, US.
Formal Peers
- 2014. Special Topics in HPV Infection. Visiting. Toluca, MX.
Grant & Contract Support
| Date: | 2024 - 2028 |
| Title: | Low-dose radiotherapy (LD-XRT) for target induction and enhancement of CAR-T cell therapy in solid tumors |
| Funding Source: | American Cancer Society (ACS) |
| Role: | PI |
| Date: | 2023 - 2024 |
| Title: | Low-dose radiotherapy (LD-XRT) in target induction and enhancement of CAR-T cell therapy in solid tumors |
| Funding Source: | MD Anderson Caner Center |
| Role: | PI |
| ID: | Institutional Research Grant |
| Date: | 2023 - 2025 |
| Title: | Low-dose radiotherapy combined with CAR T cell therapy: mechanical profiling to predict therapeutic response in solid tumors |
| Funding Source: | ARTIDIS, AG |
| Role: | Co-PI |
| Date: | 2022 - 2025 |
| Title: | Preclinical Proposal to Assess the Efficacy of Low-Dose Radiotherapy Combined with Kiromic Biopharma Gamma Delta T Cells |
| Funding Source: | Kiromic Biopharma |
| Role: | Co-PI |
| Date: | 2022 - 2025 |
| Title: | Improved therapy for solid tumors through the novel combination of low-dose radiation with T cells bearing enhanced, mesothelin-targeting TCR chimeras |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Date: | 2022 - 2025 |
| Title: | Studying the function of low-dose radiotherapy (LD-XRT) in enhancing the efficacy of novel radiation induced targeted CAR-T cell therapy for solid tumors |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2018 - 2021 |
| Title: | MUTATIONS IN EPIGENETIC REGULATORS AND IMMUNE EVASION IN LYMPHOMA |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RFA R - 19.1 - IIRA |
| Date: | 2017 - 2020 |
| Title: | MUTATIONS IN EPIGENETIC REGULATORS AND IMMUNE EVASION IN LYMPHOMA |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| ID: | Leukemia & Lymphoma Society |
| Date: | 2017 - 2018 |
| Title: | Studying EZH2 mutations in lymphomagenesis and tumor evasion mechanisms |
| Funding Source: | Leukemia Research Foundation |
| Role: | PI |
| ID: | Leukemia Research Foundation 2017-2018 funding cylce |
| Date: | 2013 - 2015 |
| Title: | Regulation of T-cell function and autoimmune inflammation by deubiquitinase CYLD |
| Funding Source: | NIH/NIAID |
| Role: | Co-I |
| ID: | 3R01AI064639 |
| Date: | 2011 - 2012 |
| Title: | The critical Role of the non-homologous end joining protein Ku70 in the homeostasis of the colorectal mucosa |
| Funding Source: | M.D. Anderson's G.S. Hogan Gastrointestinal Research Fund |
| Role: | PI |
| Date: | 2010 - 2011 |
| Title: | The role of chromosomal positioning in the generation instability in an animal model of Burkitt's lymphoma |
| Funding Source: | MDACC Lymphoma SPORE Caree Development Program |
| Role: | PI |
| Date: | 2010 - 2012 |
| Title: | Preventing tumorigenesis in developing lymphocytes |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | RO1 CA116933 |
| Title: | Investigating the Synergistic Impact of Low-Dose Radiotherapy (LDRT) and Cell Therapy on Antitumor Immune Responses |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | A Scalable GAN–GAF Framework for Reliable Reconstruction and Synthetic Expansion of Irregular Clinical Time Series |
| Funding Source: | UT |
| Role: | PI |
| Title: | Overcoming Missing Data in Radiation Oncology Research Using Novel Machine Learning Imputation Techniques |
| Funding Source: | RADIATION ONCOLOGY STRATEGIC INITIATIVES |
| Role: | PI |
| Title: | Development and Evaluation of a Novel CAR T Cell Therapy Combined with LDRT and Anti-PD-1 Blockade for Metastatic Uveal Melanoma |
| Funding Source: | Department of Defense |
| Role: | PI |
| Title: | A Generative Adversarial Framework for Imputation, Augmentation, and Forecasting of Clinical Time Series Data |
| Funding Source: | American Cancer Society |
| Role: | PI |
| Title: | Radiation-Induced PD-L1–Driven Lipid Metabolic Reprogramming Establishes Spatial Niches of Radioresistance and Immune Suppression in NSCLC |
| Funding Source: | RO |
| Role: | Co-PI |
| Title: | A Generative Adversarial Framework for Imputation, Augmentation, and Forecasting of Clinical Time Series Data |
| Funding Source: | NIH |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Freitas-Cortez, MA, Masrorpour, F, Jiang, H, Mahmud, I, Lu, Y, Huang, A, Duong, LK, Wang, Q, Voss, TA, Kettlun Leyton, C, Wei, B, Chan, W, Lin, H, Zhang, J, Tsouko, E, Ganjoo, S, Barsoumian, H, Riad, TS, Hu, Y, Leuschner, C, Puebla-Osorio, N, Wang, J, Hu, J, Davies, MA, Puduvalli, VK, Billon, C, Burris, TP, Lorenzi, PL, Gan, B, Welsh, J. Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins. Molecular cancer 24(1), 2025. e-Pub 2025. PMID: 39901247.
- Rafiq Z, Bashir T, Lu W, Puebla-Osorio N. Integrating AI, Machine Learning, and Animal Models for Precision Oncology: Bridging Preclinical and Clinical Gaps. ACS Pharmacol Transl Sci 8(10):3677-3683, 2025. e-Pub 2025. PMID: 41098564.
- Puebla-Osorio N. Enhanced Tumor Control and Survival in Preclinical Models with Adoptive Cell Therapy Preceded by Low-Dose Radiotherapy. Frontiers in Oncology 14, 2024. e-Pub 2024. PMID: 39445067.
- Yun Hu. Superior Antitumor Immune Response Achieved with Proton over Photon Immunoradiotherapy is Amplified by the Nanoradioenhancer NBTXR3. J Nanobiotechnology 22(1), 2024. e-Pub 2024. PMID: 39354474.
- He K, Puebla-Osorio N, Barsoumian HB, Sezen D, Rafiq Z, Riad TS, Hu Y, Huang A, Voss TA, Leyton CSK, Schuda LJ, Hsu E, Heiber J, Cortez MA, Welsh JW. Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. J Exp Clin Cancer Res 43(1):251, 2024. e-Pub 2024. PMID: 39218928.
- Rezvan A, Romain G, Fathi M, Heeke D, Martinez-Paniagua M, An X, Bandey IN, Montalvo MJ, Adolacion JRT, Saeedi A, Sadeghi F, Fousek K, Puebla-Osorio N, Cooper LJN, Bernatchez C, Singh H, Ahmed N, Mattie M, Bot A, Neelapu S, Varadarajan N. Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling. Nat Cancer 5(7):1010-1023, 2024. e-Pub 2024. PMID: 38750245.
- Hu, Y, Revenko, A, Barsoumian, H, Bertolet, G, Fowlkes, NW, Maazi, H, Green, MM, He, K, Sezen, D, Voss, TA, Leyton, CK, Masrorpour, F, Rafiq, Z, Puebla-Osorio, N, Leuschner, C, MacLeod, R, Cortez, MA, Welsh, J. Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy. Journal of Experimental and Clinical Cancer Research 43(1), 2024. e-Pub 2024. PMID: 38443968.
- He K, Hong DS, Ke D, Kebriaei P, Wang T, Danesi H, Bertolet G, Leuschner C, Puebla-Osorio N, Voss TA, Lin Q, Norry E, Fracasso PM, Welsh JW. Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report. Melanoma Res 33(4):332-337, 2023. e-Pub 2023. PMID: 37325860.
- Hu Y, Paris S, Sahoo N, Bertolet G, Wang Q, Wang Q, Barsoumian HB, Da Silva J, Huang A, Doss DJ, Pollock DP, Hsu E, Selene N, Leyton CSK, Voss TA, Masrorpour F, Ganjoo S, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection. JCI Insight 8(12), 2023. e-Pub 2023. PMID: 37345658.
- He K, Barsoumian HB, Puebla-Osorio N, Hu Y, Sezen D, Wasley MD, Bertolet G, Zhang J, Leuschner C, Yang L, Kettlun Leyton CS, Fowlkes NW, Green MM, Hettrick L, Chen D, Masrorpour F, Gu M, Maazi H, Revenko AS, Cortez MA, Welsh JW. Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer. Cancer Immunol Res 11(4):486-500, 2023. e-Pub 2023. PMID: 36700864.
- Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Shpall EJ, Neelapu SS, Nieto Y, Strati P. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica 108(4):1163-1167, 2023. e-Pub 2023. PMID: 36384251.
- Hu Y, Paris S, Bertolet G, Barsoumian HB, He K, Sezen D, Chen D, Wasley M, Silva JD, Mitchell JA, Voss TA, Masrorpour F, Leyton CK, Yang L, Leuschner C, Puebla-Osorio N, Gandhi S, Nguyen QN, Cortez MA, Welsh JW. Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer. J Nanobiotechnology 20(1):417, 2022. e-Pub 2022. PMID: 36123677.
- Barsoumian HB, Sezen D, Menon H, Younes AI, Hu Y, He K, Puebla-Osorio N, Wasley M, Hsu E, Patel RR, Yang L, Cortez MA, Welsh JW. High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses. Cancers (Basel) 14(1), 2022. e-Pub 2022. PMID: 35008385.
- Sezen D, Barsoumian HB, He K, Hu Y, Wang Q, Abana CO, Puebla-Osorio N, Hsu EY, Wasley M, Masrorpour F, Wang J, Cortez MA, Welsh JW. Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. Front Immunol 13:984318, 2022. e-Pub 2022. PMID: 36275767.
- Hu Y, Paris S, Bertolet G, Barsoumian HB, Wang Q, Da Silva J, Patel NB, Nguyen N, Doss DJ, Huang A, Hsu E, Leyton CSK, Voss TA, Masrorpour F, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model. Front Immunol 13:1022011, 2022. e-Pub 2022. PMID: 36405757.
- He, K, Barsoumian, H, Sezen, D, Puebla-Osorio, N, Hsu, EY, Verma, V, Abana, CO, Chen, D, Patel, RR, Gu, M, Cortez, MA, Welsh, J. Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer. Frontiers in Oncology 11, 2021. e-Pub 2021. PMID: 34497773.
- He K, Barsoumian HB, Sezen D, Puebla-Osorio N, Hsu EY, Verma V, Abana CO, Chen D, Patel RR, Gu M, Cortez MA, Welsh JW. Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer. Front Oncol 11:737425, 2021. e-Pub 2021.
- Mueller-Schoell A, Puebla-Osorio N, Michelet R, Green MR, Künkele A, Huisinga W, Strati P, Chasen B, Neelapu SS, Yee C, Kloft C. Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers (Basel) 13(11), 2021. e-Pub 2021. PMID: 34205020.
- Younes AI, Barsoumian HB, Sezen D, Verma V, Patel R, Wasley M, Hu Y, Dunn JD, He K, Chen D, Menon H, Masrorpour F, Gu M, Yang L, Puebla-Osorio N, Cortez MA, Welsh JW. Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity. Transl Oncol 14(2):100983, 2021. e-Pub 2021. PMID: 33340886.
- Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26(12):1878-1887, 2020. e-Pub 2020. PMID: 33020644.
- Harden, A, Puebla-Osorio, N, and Schadler K. Modifiers of Endothelial Permeability in the Setting of CAR-t Therapy Related Immune Cell Associated Neurotoxicity Syndrome. Biology of Blood and Marrow Transplantation 26(3):258, 2020. e-Pub 2020.
- Zhang H, Li HS, Hillmer EJ, Zhao Y, Chrisikos TT, Hu H, Wu X, Thompson EJ, Clise-Dwyer K, Millerchip KA, Wei Y, Puebla-Osorio N, Kaushik S, Santos MA, Wang B, Garcia-Manero G, Wang J, Sun SC, Watowich SS. Genetic rescue of lineage-balanced blood cell production reveals a crucial role for STAT3 anti-inflammatory activity in hematopoiesis. Proc Natl Acad Sci U S A 115(10):E2311-E2319, 2018. e-Pub 2018. PMID: 29463696.
- Campillo-Navarro M, Leyva-Paredes K, Donis-Maturano L, Rodríguez-López GM, Soria-Castro R, García-Pérez BE, Puebla-Osorio N, Ullrich SE, Luna-Herrera J, Flores-Romo L, Sumano-López H, Pérez-Tapia SM, Estrada-Parra S, Estrada-García I, Chacón-Salinas R. Mycobacterium tuberculosis Catalase Inhibits the Formation of Mast Cell Extracellular Traps. Front Immunol 9:1161, 2018. e-Pub 2018. PMID: 29892297.
- Damiani E, Puebla-Osorio N, Lege BM, Liu J, Neelapu SS, Ullrich SE. Platelet activating factor up-regulates p21 expression in human mast cells via histone acetylation. Sci Rep 7:41959, 2017. e-Pub 2017. PMID: 28157211.
- Puebla-Osorio N, Sarchio SNE, Ullrich SE, Byrne SN. Detection of Infiltrating Mast Cells Using a Modified Toluidine Blue Staining. Methods Mol Biol 1627:213-222, 2017. e-Pub 2017. PMID: 28836204.
- Damiani E, Puebla-Osorio N, Gorbea E, Ullrich SE. Platelet-Activating Factor Induces Epigenetic Modifications in Human Mast Cells. J Invest Dermatol 135(12):3034-40, 2015. e-Pub 2015. PMID: 26316070.
- Puebla-Osorio N, Damiani E, Bover L, Ullrich SE. Platelet-activating factor induces cell cycle arrest and disrupts the DNA damage response in mast cells. Cell Death Dis 6:e1745, 2015. e-Pub 2015. PMID: 25950475.
- Sun M, Zhou C, Zeng H, Puebla-Osorio N, Damiani E, Chen J, Wang H, Li G, Yin F, Shan L, Zuo D, Liao Y, Wang Z, Zheng L, Hua Y, Cai Z. Hiporfin-mediated photodynamic therapy in preclinical treatment of osteosarcoma. Photochem Photobiol 91(3):e1745. doi: 10.1038/cddis.2015.115, 2015. e-Pub 2015. PMID: 25619546.
- Puebla-Osorio N, Kim J, Ojeda S, Zhang H, Tavana O, Li S, Wang Y, Ma Q, Schluns KS, Zhu C. A novel Ku70 function in colorectal homoeostasis separating from nonhomologous end joining. Oncogene 33(21):2748-57, 2014. e-Pub 2014. PMID: 23752193.
- Chang JH, Hu H, Jin J, Puebla-Osorio N, Xiao Y, Gilbert BE, Brink R, Ullrich SE, Sun SC. TRAF3 regulates the effector function of regulatory T cells and humoral immune responses. J Exp Med 211(1):137-51, 2014. e-Pub 2014. PMID: 24378539.
- Tavana O, Puebla-Osorio N, Kim J, Sang M, Jang S, Zhu C. Ku70 functions in addition to nonhomologous end joining in pancreatic β-cells: a connection to β-catenin regulation. Diabetes 62(7):2429-38, 2013. e-Pub 2013. PMID: 23474484.
- Hu H, Brittain GC, Chang JH, Puebla-Osorio N, Jin J, Zal A, Xiao Y, Cheng X, Chang M, Fu YX, Zal T, Zhu C, Sun SC. OTUD7B controls non-canonical NF-κB activation through deubiquitination of TRAF3. Nature 494(7437):371-4, 2013. e-Pub 2013. PMID: 23334419.
- Puebla-Osorio N, Miyahara Y, Coimbatore S, Limón-Flores AY, Kazimi N, Ullrich SE, Zhu C. Induction of B-cell lymphoma by UVB radiation in p53 haploinsufficient mice. BMC Cancer 11:36, 2011. e-Pub 2011. PMID: 21269511.
- Tavana O, Benjamin CL, Puebla-Osorio N, Sang M, Ullrich SE, Ananthaswamy HN, Zhu C. Absence of p53-dependent apoptosis leads to UV radiation hypersensitivity, enhanced immunosuppression and cellular senescence. Cell Cycle 9(16):3328-36, 2010. e-Pub 2010. PMID: 20703098.
- Dujka ME, Puebla-Osorio N, Tavana O, Sang M, Zhu C. ATM and p53 are essential in the cell-cycle containment of DNA breaks during V(D)J recombination in vivo. Oncogene 29(7):957-65, 2010. e-Pub 2010. PMID: 19915617.
- Tavana O, Puebla-Osorio N, Sang M, Zhu C. Absence of p53-dependent apoptosis combined with nonhomologous end-joining deficiency leads to a severe diabetic phenotype in mice. Diabetes 59(1):135-42, 2010. e-Pub 2010. PMID: 19833883.
- Van Nguyen T, Puebla-Osorio N, Pang H, Dujka ME, Zhu C. DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model. J Exp Med 204(6):1453-61, 2007. e-Pub 2007. PMID: 17535972.
- Puebla-Osorio N. Low Dose Radiation Enhanced Antitumor Immune Response by Reprogramming T-Cell Metabolism in Tumor Immune Microenvironment. Oncogene. e-Pub 2007.
- Puebla-Osorio N, Lacey DB, Alt FW, Zhu C. Early embryonic lethality due to targeted inactivation of DNA ligase III. Mol Cell Biol 26(10):3935-41, 2006. e-Pub 2006. PMID: 16648486.
- Puebla-Osorio N, Ramos KS, Falahatpisheh MH, Smith R, Berghman LR. 2,3,7,8-Tetrachlorodibenzo-p-dioxin elicits aryl hydrocarbon receptor-mediated apoptosis in the avian DT40 pre-B-cell line through activation of caspases 9 and 3. Comp Biochem Physiol C Toxicol Pharmacol 138(4):461-8, 2004. e-Pub 2004. PMID: 15536054.
- Kingsley RA, Abi Ghanem D, Puebla-Osorio N, Keestra AM, Berghman L, Bäumler AJ. Fibronectin binding to the Salmonella enterica serotype Typhimurium ShdA autotransporter protein is inhibited by a monoclonal antibody recognizing the A3 repeat. J Bacteriol 186(15):4931-9, 2004. e-Pub 2004. PMID: 15262930.
- Puebla-Osorio N, Proudman JA, Compton AE, Clements KE, Decuypere E, Vandesande F, Berghman LR. FSH- and LH-cells originate as separate cell populations and at different embryonic stages in the chicken embryo. Gen Comp Endocrinol 127(3):242-8, 2002. e-Pub 2002. PMID: 12225765.
- Berghman, LR, D’Hondt, E, Puebla, N, Dees, L, Hiney, J, Sower, S, Vandesande A, F. Immunocytochemical evidence for the existence of a lamprey luteinizing hormone-releasing hormone type III-like peptide in the chicken hypothalamus. British Poult. Sci 41(1):56-57, 2000. e-Pub 2000.
Review Articles
- Manzar, G, Hasan, MF, Moore, M, Tiberti, S, Puebla-Osorio, N, Basar, R, Daher, M. Advancing CAR-NK cell therapy in solid tumors. Cell Reports Medicine 7(7), 2026. e-Pub 2026. PMID: 42349415.
- Rafiq, Z, Kang, M, Barsoumian, H, Manzar, G, Hu, Y, Leuschner, C, Huang, A, Masrorpour, F, Lu, W, Puebla-Osorio, N, Welsh, J. Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma. Journal of Experimental and Clinical Cancer Research 44(1), 2025. e-Pub 2025. PMID: 39881333.
- Robinson DJ, Barsoumian HB, Nalin AP, Verma V, Niedzielski JS, Puebla-Osorio N, Hu Y, Kang M, Shah SJ, Phan J, Welsh JW. Real-World Guide for Delivering Immunotherapy With Radiation Therapy. Pract Radiat Oncol, 2025. e-Pub 2025. PMID: 41061930.
- Barsoumian, H, Hsu, J, Nanez, S, Hu, Y, Hsu, EY, Riad, TS, Puebla-Osorio, N, Cortez, MA, Welsh, J. The RadScopal Technique as an Immune Adjuvant to Treat Cancer. Immuno 3(1):74-85, 2023. e-Pub 2023.
- Ganjoo S, Puebla-Osorio N, Nanez S, Hsu E, Voss T, Barsoumian H, Duong LK, Welsh JW, Cortez MA. Bone morphogenetic proteins, activins, and growth and differentiation factors in tumor immunology and immunotherapy resistance. Front Immunol 13:1033642, 2022. e-Pub 2022. PMID: 36353620.
- He, K, Barsoumian, H, Bertolet, G, Verma, V, Leuschner, C, Koay, EJ, Ludmir, EB, Hsu, EY, Pisipati, E, Voss, TA, Puebla-Osorio, N, Cortez, MA, Welsh, J. Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases. Frontiers in immunology 12, 2021. e-Pub 2021. PMID: 34975924.
- Sezen D, Verma V, He K, Abana CO, Barsoumian H, Ning MS, Tang C, Hurmuz P, Puebla-Osorio N, Chen D, Tendler I, Comeaux N, Nguyen QN, Chang JY, Welsh JW. Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Semin Radiat Oncol 31(3):217-226, 2021. e-Pub 2021. PMID: 34090648.
- Patel RR, Verma V, Barsoumian HB, Ning MS, Chun SG, Tang C, Chang JY, Lee PP, Gandhi S, Balter P, Dunn JD, Chen D, Puebla-Osorio N, Cortez MA, Welsh JW. Use of Multi-Site Radiation Therapy for Systemic Disease Control. Int J Radiat Oncol Biol Phys 109(2):352-364, 2021. e-Pub 2021. PMID: 32798606.
- Soria-Castro R, Schcolnik-Cabrera A, Rodríguez-López G, Campillo-Navarro M, Puebla-Osorio N, Estrada-Parra S, Estrada-García I, Chacón-Salinas R, Chávez-Blanco AD. Exploring the drug repurposing versatility of valproic acid as a multifunctional regulator of innate and adaptive immune cells. J Immunol Res 9678098:9678098, 2019. e-Pub 2019. PMID: 31001564.
- Puebla-Osorio N, Zhu C. DNA damage and repair during lymphoid development: antigen receptor diversity, genomic integrity and lymphomagenesis. Immunol Res 41(2):103-22, 2008. e-Pub 2008. PMID: 18214391.
Professional Educational Materials
- Puebla-Osorio N. Detection of Infiltrating Mast Cells Using a Modified Toluidine Blue Staining. SpringerLink, 2017.
- Puebla-Osorio N, Heiko Enderling. Modeling of Tumor Trajectories in Motion.
Other Articles
- He, K, Puebla-Osorio, N, Barsoumian, H, Sezen, D, Rafq, Z, Riad, TS, Hu, Y, Huang, A, Voss, TA, Kettlun Leyton, C, Schuda, L, Hsu, EY, Heiber, J, Cortez, MA, Welsh, J Correction to. Journal of Experimental and Clinical Cancer Research 43(1), 2024. PMID: 39256857.
- Rezvan, A, Romain, G, Fathi, M, Heeke, D, Martinez Paniagua, M, An, X, Bandey, I, Montalvo, MJ, Adolacion, JR, Saeedi, A, Sadeghi, F, Fousek, K, Puebla-Osorio, N, Cooper, L, Bernatchez, C, Singh, H, Ahmed, NM, Mattie, M, Bot, A, Neelapu, SS, Varadarajan, N Correction to. Nature Cancer 5(6):954, 2024. PMID: 38778179.
Editorials
- Flati, V, Di Gregorio, J, Puebla-Osorio, N, Kashfi, K. Editorial. Frontiers in immunology 17, 2026. PMID: 41607527.
Abstracts
- Puebla-Osorio N. Geometric Adversarial Learning for Reconstruction of Right-Censored Tumor Dynamics. University of Graz.
- Puebla-Osorio N. Tissue nanomechanics as a novel, clinically translatable predictive early biomarker of response in combination immunotherapy. AACR.
- Puebla-Osorio N. Low-dose radiation-powered immunotherapy reshapes tissue nanomechanics: a tumor-agnostic approach to restore tumor response. SITC Annual Meeting 2025.
- Puebla-Osorio N, Heiko Enderling. Enabling Robust Digital Twins Through End-to-End GAN-GAF Framework for Clinical Time Series Generation and Imputation. Second Annual Digital Twin Summit.
- Puebla-Osorio N, Heiko Enderling. Enabling Robust Digital Twins Through End-to-End GAN-GAF Framework for Clinical Time Series Generation and Imputation. MathOnco25 Conference.
- Puebla-Osorio N. Ab Initio Generative Framework for Time-Series Imputation in Radiotherapy Modeling. Stockholmsmassan.
- Puebla-Osorio N, Heiko Enderling. Ab Initio Generative Framework for Time-Series Imputation in Radiotherapy Modeling. European Society for Radiotherapy and Oncology.
Book Chapters
- He, K, Selek, U, Barsoumian, H, Sezen, D, Ning, M, Puebla-Osorio, N, Schoenhals, JE, Chen, D, Leuschner, C, Cortez, MA, Welsh, J. Mechanisms of Action of Radiotherapy and Immunotherapy in Lung Cancer. In: Advances in Radiation Oncology in Lung Cancer. SpringerLink, 399-414, 2023.
- He K, Selek U, Barsoumian HB, Sezen D, Ning MS, Puebla-Osorio N, Schoenhals JE, Chen D, Leuschner C, Cortez MA, Welsh JW. Mechanisms of Action of Radiotherapy and Immunotherapy in Lung Cancer: Implications for Clinical Practice. In: Medical Radiology. Springer Science and Business Media Deutschland GmbH, 2022.
- Puebla-Osorio, Strati N, P, and Neelapu S. The tumor microenvironment in follicular lymphoma. In: Follicular Lymphoma. Springer Cham, 65-82, 2020.
- Puebla-Osorio N, Sarchio SN, Ullrich SE, Byrne SN. Chapter 14:Detection of infiltrating mast cells using a modified toluidine blue staining. In: Methods in Molecular Biology. Springer, 213-222, 2017.
Patient Reviews
CV information above last modified August 18, 2026